The beta-lactamase inhibitor Sulbactam, in the form of a powder for the preparation of a solution for intravenous and intramuscular administration, has been added to the product range of PJSC "Krasfarma."

Sulbactam is a proven, reliable, and effective drug in the fight against microbial resistance. By preventing the breakdown of penicillins and cephalosporins by beta-lactamases produced by Gram-negative bacteria, it provides a bactericidal effect, microbiological, and clinical efficacy in infections caused by resistant pathogens. Furthermore, Sulbactam is highly active against Acinetobacter, one of the most problematic causes of hospital-acquired infections, and members of the Neisseriaceae family.

Sulbactam can be used in combination with other beta-lactams or independently in cases of infections caused by Acinetobacter. It has a high safety profile, similar to penicillins and cephalosporins, and can be used in both neonates and adults.

The product range of PJSC "Krasfarma" already includes beta-lactamase-protected penicillins (ampicillin + sulbactam) and cephalosporins (cefotaxime + sulbactam). With the launch of Sulbactam, there is now the potential for broad clinical use of combinations with other cephalosporins produced by the company, which should enhance the effectiveness of treatments and prevent the further spread of resistant strains.

View in catalog